Please login to the form below

Not currently logged in
Email:
Password:

Linda Law joins Advicenne as US VP, clinical development and med affairs

She will oversee the biopharma’s developments with its dTRA candidate

Linda Late-stage biopharmaceutical company Advicenne has appointed Linda Law as its new US vice president of clinical development and medical affairs.

Law will take responsibility for the group’s efforts in North America, which are focused on its distal Renal Acidosis (dTRA) candidate and she will report to Advicenne’s chief executive officer Dr Luc-André Granier.

She brings 20 years’ of experience in international pharmaceutical development and medical affairs across a range of therapeutic areas to the group.

Commenting on her appointment, Granier said: “This is a pivotal time for Advicenne and Dr Law’s experience and deep knowledge of US clinical development will be of great value of Advicenne.

“Her appointment also marks the start of the company’s US operations.”

Law’s career has seen her serve in various positions for pharmaceutical companies including Procter & Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and Forest Pharmaceuticals.

1st February 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics